| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1002/PHAR.1946 |
| P8608 | Fatcat ID | release_lv5zhgxztvfvxi7vzgwoo3jf34 |
| P698 | PubMed publication ID | 28494109 |
| P50 | author | Jennifer C Y Jupp | Q89254976 |
| P2093 | author name string | Roger Y Tsang | |
| Vincent H Ha | |||
| P2860 | cites work | The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence | Q24311466 |
| Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1 | Q27004072 | ||
| Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome) | Q28295988 | ||
| Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. | Q33425469 | ||
| Molecular genetic basis of Gilbert's syndrome | Q33756586 | ||
| Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism | Q33834417 | ||
| Hepatotoxicity of chemotherapy | Q33942794 | ||
| Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics | Q34041139 | ||
| The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome | Q34057969 | ||
| Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer | Q34565071 | ||
| Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis. | Q34820468 | ||
| Ancestry and pharmacogenetics of antileukemic drug toxicity | Q35828717 | ||
| Therapeutic drug monitoring of cancer chemotherapy. | Q37018328 | ||
| Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question | Q37249563 | ||
| Population pharmacokinetic analysis of axitinib in healthy volunteers | Q37635202 | ||
| Gilbert syndrome | Q37967241 | ||
| Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study | Q39101901 | ||
| Outcome and toxicities associated to chemotherapy in children with acute lymphoblastic leukemia and Gilbert syndrome. Usefulness of UGT1A1 mutational screening. | Q41099201 | ||
| UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib | Q43293587 | ||
| Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms. | Q43963256 | ||
| Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia. | Q44302313 | ||
| Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. | Q44384003 | ||
| Glucuronidation of Etoposide in Human Liver Microsomes Is Specifically Catalyzed by UDP-Glucuronosyltransferase 1A1 | Q44403623 | ||
| Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation? | Q44791732 | ||
| Doxorubicin dosage guidelines in a patient with hyperbilirubinemia of Gilbert's syndrome | Q45114480 | ||
| Nilotinib-induced hyperbilirubinemia: is it a negligible adverse event? | Q45984197 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Gilbert syndrome | Q752216 |
| P304 | page(s) | 956-972 | |
| P577 | publication date | 2017-05-11 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Oncology Drug Dosing in Gilbert Syndrome Associated with UGT1A1: A Summary of the Literature | |
| P478 | volume | 37 |
| Q64114732 | Association Study Among Candidate Genetic Polymorphisms and Chemotherapy-Related Severe Toxicity in Testicular Cancer Patients |
| Q89678032 | Carbon monoxide breath test assessment of mild hemolysis in Gilbert's syndrome |
| Q99711709 | Gilbert syndrome with systemic lupus erythematosus presenting with persistent unconjugated hyperbilirubinemia: A case report |
| Q58695636 | UGT1A1 (TA)n promoter genotype: Diagnostic and population pharmacogenetic marker in Serbia |
Search more.